The CAR-HAMATOTOX for risk stratification of severe infections and for the adjustment of antibacterial prophylaxis prior to CD19-targeted CAR T-cell therapy

Rejeski K, Perez A, Iacoboni G, Penack O, Buecklein , Mougiakakos D, Blumenberg , Hoster E, Bullinger L, Locke F, Von Bergwelt-Baildon M, Mackensen A, Bethge W, Barba P, Jain M, Subklewe M (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Oncology Research and Treatment Karger Publishers

Publisher: KARGER

City/Town: BASEL

Pages Range: 250-250

Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT

Authors with CRIS profile

Dimitrios Mougiakakos Medizinische Fakultät Andreas Mackensen Lehrstuhl für Innere Medizin V

Involved external institutions

Ludwig-Maximilians-Universität (LMU) DE Germany (DE) H. Lee Moffitt Cancer Center & Research Institute US United States (USA) (US) Vall d'Hebron University Hospital / Hospital Universitari Vall d'Hebron ES Spain (ES) Charité - Universitätsmedizin Berlin DE Germany (DE) Universitätsklinikum Tübingen DE Germany (DE)

How to cite

APA:

Rejeski, K., Perez, A., Iacoboni, G., Penack, O., Buecklein, ., Mougiakakos, D.,... Subklewe, M. (2022). The CAR-HAMATOTOX for risk stratification of severe infections and for the adjustment of antibacterial prophylaxis prior to CD19-targeted CAR T-cell therapy. In ONCOLOGY RESEARCH AND TREATMENT (pp. 250-250). BASEL: KARGER.

MLA:

Rejeski, K., et al. "The CAR-HAMATOTOX for risk stratification of severe infections and for the adjustment of antibacterial prophylaxis prior to CD19-targeted CAR T-cell therapy." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2022. 250-250.

BibTeX: Download